The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 02, 2020

Filed:

Nov. 03, 2017
Applicant:

Immunomedics, Inc., Morris Plains, NJ (US);

Inventors:

Chien-Hsing Chang, Downingtown, PA (US);

David M. Goldenberg, Mendham, NJ (US);

Assignee:

Immunomedics, Inc., Morris Plains, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 38/21 (2006.01); A61P 35/00 (2006.01); A61K 47/68 (2017.01); C07K 16/30 (2006.01); C07K 16/44 (2006.01); A61P 35/04 (2006.01); A61K 47/60 (2017.01); A61K 31/4745 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2818 (2013.01); A61K 31/4745 (2013.01); A61K 38/21 (2013.01); A61K 38/212 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/60 (2017.08); A61K 47/6803 (2017.08); A61K 47/6851 (2017.08); A61K 47/6857 (2017.08); A61K 47/6859 (2017.08); A61K 47/6863 (2017.08); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/2833 (2013.01); C07K 16/2863 (2013.01); C07K 16/2887 (2013.01); C07K 16/30 (2013.01); C07K 16/3007 (2013.01); C07K 16/44 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention concerns compositions and methods of use of anti-PD-1 antibodies comprising CDR sequences corresponding to SEQ ID NO:1 to SEQ ID NO:6. Preferably the antibody is a humanized antibody comprising the variable region amino acid sequences of SEQ ID NO: 9 and SEQ ID NO:10. The antibodies are of use to treat cancer and may be administered alone or with another standard anti-cancer therapy. The methods may comprise administering the anti-PD-1 antibody or antigen-binding fragment thereof in combination with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-α), and/or other checkpoint inhibitor antibodies.


Find Patent Forward Citations

Loading…